EGFR and non-small cell lung carcinoma: In the phase 1 CHRYSALIS trial, amivantamab elicited an ORR of 40%, a median PFS of 8.3 months, and a median OS of 22.8 months in EGFR exon 20 insertion-mutant NSCLC patients that were previously treated [36] and it has been granted regular approval by the FDA and EMA.